Physician profile
Daniel A Gross
NPI 1396740056
$1,796.13
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $853 · 2020: $375 · 2021: $204 · 2022: $46.00 · 2023: $259 · 2024: $59.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $318.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $243.71 | 2019 | |
| Sun Pharmaceutical Industries INC. | $228.57 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $177.45 | 2023 | Sotyktu |
| Abbvie INC. | $169.89 | 2020-2024 | |
| Biofrontera INC. | $157.00 | 2019 | |
| Dermira, INC. | $125.00 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $120.91 | 2019 | |
| Pfizer INC. | $81.31 | 2023 | |
| Cardiovascular Systems INC. | $80.83 | 2019 | |
| Janssen Biotech, INC. | $74.47 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $70.15 | 2019-2021 | |
| Lilly USA, LLC | $69.92 | 2020-2022 | |
| Amgen INC. | $56.08 | 2021 | |
| Celgene Corporation | $51.00 | 2019 | |
| Genentech USA, INC. | $36.53 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dusa Pharmaceuticals, INC. | $22.00 | 2019 | |
| Incyte Corporation | $21.11 | 2021 | |
| Prugen, INC. Pharmaceuticals | $10.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Gross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.